Twitter timeline

Promising clinical results for innovative mutated anti-EGFR radiotracer in patients with non-small cell lung cancer

December 18, 2017

  • First stage of Phase 1 clinical study completed with promising results
  • Launch of second stage to evaluate the specificity of the radiotracer
  • Full study results expected in H1 2018


Oncodesign reports positive results for its MNK1/2 program

December 5, 2017

  • MNK1 and MNK2 are kinases targeted in a major activation pathway for several cancers
  • The program has identified highly targeted inhibitor molecules and produced promising cellular results paving the way for lead optimization to begin